Venous valve apparatus, system, and method

Information

  • Patent Grant
  • 7670368
  • Patent Number
    7,670,368
  • Date Filed
    Monday, February 7, 2005
    19 years ago
  • Date Issued
    Tuesday, March 2, 2010
    14 years ago
Abstract
A venous valve with a frame and a cover on the frame for unidirectional flow of a liquid through the valve.
Description
FIELD OF THE INVENTION

The present invention relates generally to apparatus, systems, and methods for use in a lumen; and more particularly to a valve apparatus, systems, and methods for use in the vasculature system.


BACKGROUND OF THE INVENTION

The venous system of the legs uses valves and muscles as part of the body's pumping mechanism to return blood to the heart. Venous valves create one way flow to prevent blood from flowing away from the heart. When valves fail, blood can pool in the lower legs resulting in swelling and ulcers of the leg. The absence of functioning venous valves can lead to chronic venous insufficiency.


Techniques for both repairing and replacing the valves exist, but are tedious and require invasive surgical procedures. Direct and indirect valvuloplasty procedures are used to repair damaged valves. Transposition and transplantation are used to replace an incompetent valve. Transposition involves moving a vein with an incompetent valve to a site with a competent valve. Transplantation replaces an incompetent valve with a harvested valve from another venous site. Prosthetic valves can be transplanted into the venous system, but current devices are not successful enough to see widespread usage.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 illustrates an embodiment of a valve.



FIG. 2 illustrates an embodiment of a valve.



FIG. 3 illustrates an embodiment of a valve.



FIGS. 4A-4F illustrate embodiments of cross-sectional geometries for use with embodiments of a valve.



FIGS. 5A-5B illustrate a valve in an expanded and collapsed state.



FIGS. 6A-6D illustrate an embodiment of a valve.



FIG. 7 illustrates an embodiment of a system that includes a valve.



FIG. 8 illustrates an embodiment of a system that includes a valve.



FIG. 9 illustrates an embodiment of a system that includes a valve.





DETAILED DESCRIPTION

Embodiments of the present invention are directed to an apparatus, system, and method for valve replacement or augmentation. For example, the apparatus can include a valve that can be used to replace or augment an incompetent valve in a body lumen. Embodiments of the valve can include a frame and cover that can be implanted through minimally-invasive techniques into the body lumen. In one example, embodiments of the apparatus, system, and method for valve replacement or augmentation may help to maintain antegrade blood flow, while decreasing retrograde blood flow in a venous system of individuals having venous insufficiency, such as venous insufficiency in the legs.


The Figs. herein follow a numbering convention in which the first digit or digits correspond to the drawing Fig. number and the remaining digits identify an element or component in the drawing. Similar elements or components between different Figs. may be identified by the use of similar digits. For example, 110 may reference element “10” in FIG. 1, and a similar element may be referenced as 210 in FIG. 2. As will be appreciated, elements shown in the various embodiments herein can be added, exchanged, and/or eliminated so as to provide a number of additional embodiments of valve. In addition, discussion of features and/or attributes for an element with respect to one Fig. can also apply to the element shown in one or more additional Figs.



FIGS. 1-3 provide illustrations of various embodiments of a valve of the present invention. Generally, the valve can be implanted within the fluid passageway of a body lumen, such as for replacement or augmentation of a valve structure within the body lumen (e.g., a venous valve). In one embodiment, the valve of the present invention may be beneficial to regulate the flow of a bodily fluid through the body lumen in a single direction.



FIG. 1 illustrates one embodiment of a venous valve 100. Venous valve 100 includes a frame 102 and a cover 104 for the venous valve 100, where both the frame 102 and the cover 104 can resiliently radially collapse and expand, as will be discussed herein. Among other things, the frame 102 and the cover 104 define a lumen 105 of the valve 100. Lumen 105 allows for, amongst other things, fluid to move through the valve 100.


The frame 102 of valve 100 can have a number of configurations. For example, in the various embodiments the frame 102 can include at least a first planar surface 106 having a predetermined width 108. In one embodiment, the first planar surface 106 extends along the entire length of the frame 102, as illustrated in the embodiment of FIG. 1. In an additional embodiment, the first planar surface 106 can be present along one or more predetermined portions of the frame 102, as illustrated in FIGS. 2 and 3.


As illustrated in FIGS. 1-3, the first planar surface 106 provides an essentially flat surface defining an outer diameter 110 of the frame 102. In the various embodiments, the predetermined width 108 of the first planar surface 106 can include a number of values. As will be appreciated, the predetermined width 108 can be determined based on the location in which the venous valve 100 is to be implanted.


The predetermined width 108 of the frame 102, in addition, can have a uniform value over the length of frame 102. Alternatively, the predetermined width 108 of the frame 102 can have predetermined variations over the length of the frame 102. For example, the predetermined width 108 can be larger (i.e., wider) along one or more intermediate portions 112 of the frame 102 as compared to corner portions 114 of the frame 102. The exact configuration and values for the predetermined width 108 can depend on many patient factors, including, but not limited to, where the valve 100 is to be implanted and the physiological environment in which the valve 100 is to be implanted.


In addition, the intermediate portions 112 of the frame 102 can further include at least a partial helical configuration 116. For example, the first planar surface 106 of frame 102 can follow the partial helical configuration 116 extending along a longitudinal central axis 118 of the frame 102 such that the first planar surface 106 maintains an essentially symmetrical relation to the outer diameter 110 of the frame 102. In one embodiment, this configuration of the frame 102 allows the first planar surface 106 along the intermediate portions 112 to essentially follow along a tubular shaped path extending along the longitudinal central axis 118. In other words, the first planar surface 106 rotates (e.g., twists) as it extends along the longitudinal central axis 118 to essentially track the tubular (e.g., circular) surface along points that cross right sections of the tubular surface at an oblique angle. In addition, this configuration of the frame 102 can further allow the first planar surface 106 to essentially follow the tubular (e.g., circular) path as the frame 102 moves between a compressed and expanded state, as will be more fully discussed herein.


In the various embodiments described herein, the corner portions 114 of the frame 102 can provide a spring force to counter radial compression of the frame 102. As will be appreciated, additional spring force can be imparted to the frame 102 from the compression of the partial helical configuration 116 of the intermediate portions 112 of the frame 102 as well. For example, as all or a portion of the frame 102 is radially compressed towards the longitudinal central axis 118, both the corner portions 114 and the partial helical configuration 116 of the frame 102 can resiliently bend (e.g., the spiral shape of the partial helical configuration is turned more tightly) to store elastic force (e.g., elastic potential energy) that allows the frame 102 to expand radially so as to return towards its uncompressed state.


As illustrated in FIG. 1, the first planar surface 106 of the frame 102 can turn from its essentially symmetrical relation to the outer diameter 110 of the frame 102 to form one embodiment of the corner portions 114. So, for example, in FIG. 1 the first planar surface 106 forms an inner surface 119 of the corner portion 114. In an alternative embodiment, the first planar surface 106 of the frame 102 includes an essentially symmetrical relation to the outer diameter 110 of the frame 102 through the corner portions 114. An example of this embodiment is provided in FIGS. 2 and 3.


As illustrated in FIGS. 1-3, the frame 102 can be described as having a first member 120, a second member 122, a third member 124, and a fourth member 126. As illustrated in FIGS. 1-3, each of the first, second, third, and fourth member 120, 122, 124, and 126, each include at least the first planar surface 106. In addition, the corner portions 114 of the frame 102 provide a first vertex 128 and a second vertex 130 relative a first end 132 of the frame 102, and a third vertex 134 and a fourth vertex 136 relative the first and second vertices 128 and 130. In one embodiment, the first vertex 128 and the second vertex 130 are positioned opposite each other along a first common axis 138. Similarly, the third vertex 134 and the fourth vertex 136 are positioned opposite each other along a second common axis 140. Other relative positions for the vertices 128, 130, 134, and 136 are also possible.


As illustrated in FIGS. 1-3, the first member 120 and the second member 122 extend from the first vertex 128, and the third member 124 and the fourth member 126 extend from the second vertex 130. Similarly, the first member 120 and the third member 124 extend from the third vertex 134 at the first end 132 of the frame 102 relative the first and second vertices, 128 and 130, and the second member 122 and the fourth member 126 extend from the fourth vertex 136 at the first end 132 of the frame 102 relative the first and second vertices 128 and 130.


In the various embodiments, the frame 102 can provide symmetrical relationships for the members 120, 122, 124 and 126 and the vertices 128, 130, 134 and 136. For example, as illustrated in FIGS. 1-3 the frame 102 can provide both bilateral symmetry and radial symmetry, among other things. With respect to bilateral symmetry, the second member 122 and the fourth member 126 can have a symmetrical relationship to the first member 120 and the third member 124, respectively, across a plane extending from the first common axis 138 and bisecting the second common axis 140 perpendicularly. In other words, the second member 122 and the fourth member 126 can provide a mirror image of the first member 120 and the third member 124, respectively. Similarly, the first vertex 128 and the third vertex 134 can provide mirror images of the second vertex 130 and the fourth vertex 136, respectively.


In additional embodiments, the frame 102 can also provide radial symmetry for the members 120, 122, 124 and 126 and the vertices 128, 130, 134 and 136. For example, FIGS. 1-3 provide an illustration of radial symmetry for the members 120, 122, 124 and 126 and the vertices 128, 130, 134 and 136 around the longitudinal central axis 118 of the frame 102. As illustrated, the first member 120 and the second member 122 can be positioned approximately ninety (90) degrees relative each other around the longitudinal central axis 118 of the frame 102. Similarly, the second member 122 and the fourth member 126, the third member 124 and the fourth member 126, and the third member 124 and the first member 120 can be positioned approximately ninety (90) degrees relative each other around the longitudinal central axis 118 of the frame 102.


As will be appreciated, the various members and vertices of the frame 102 need not necessarily, however, display a symmetrical relationship in order to practice the embodiments of the present invention. For example, in an additional embodiment the radial relationship of the first member 120 and the second member 122 can be set apart approximately ninety (90) degrees or greater relative each other around the longitudinal central axis 118 of the frame 102. In which case the first member 120 and the third member 124, and the second member 122 and the fourth member 126 can be set apart approximately ninety (90) degrees or less relative each other around the longitudinal central axis 118 of the frame 102. Other radial relationships are also possible.


As illustrated in FIGS. 1-3, the frame 102 can have similar and/or different cross-sectional geometries along its length. The similarity and/or the differences in the cross-sectional geometries can be based on one or more desired functions to be elicited from each portion of the frame 102 (e.g., the members 120, 122, 124, 126, and the vertices 128, 130, 134 and 136).


For example, the frame 102 can have a similar cross-sectional geometry along its length. FIG. 1 provides an illustration of the similar cross-sectional geometry, where the frame 102 includes a second planar surface 141 interior to the frame 102 and parallel with the first planar surface 106 so as to provide a strip 142 of material to form the frame 102. The strip 142 of material forming the frame 102 includes a dimension of height 144 between the first planar surface 106 and the second planar surface 141 so as to provide an aspect ratio of the predetermined width 108 to the height 144. As will be appreciated, the aspect ratio can have one or more values that provide the frame 102 with sufficient strength, flexibility and/or rigidity for the environment, including the physical demands, in which the venous valve 100 is to be used. Embodiments of the invention are not so limited.


Alternatively, the frame 102 can include portions having the first planar surface 106 with the other portions of the frame 102 surfaces having a non-planar configuration. For example, FIGS. 2 and 3 illustrate embodiments in which the frames 202 and 302 have different cross-sectional geometries along their length. For example, FIG. 2 provides an illustration in which the corner portions 214 of the frame 202, including the vertices 228, 230, 234 and 236, can have one or more of a semi-round (e.g., semi-circular, semi-oval, and/or semi-elliptical) cross-sectional geometry, while the members 220, 222, 224, and 226 can have a strip 242 geometry, as described herein. As will be appreciated, each of the corner portions 214 of the frame 202 can themselves have similar and/or different cross-sectional geometries (e.g., corner portions 214 of vertices 228 and 230 could have a semi-circular cross-sectional geometry, while the corner portions 214 of vertices 234 and 236 could have a semi-elliptical cross-sectional geometry). Other combinations of cross-sectional geometries are possible.


While the members 220, 222, 224, and 226 are illustrated herein as having a planar cross-sectional configuration, other configurations are also possible. For example, FIGS. 4A-4F provide non-limiting examples cross-sectional geometries for one or more portions of the members 220, 222, 224, and 226, and the corner portions 214 of the frame 202. As shown in FIGS. 4A-4F, examples of cross-sectional geometries include, but are not limited to, rectangular geometries having perpendicular sides (FIG. 4A), one or more convex sides (FIG. 4D), and one or more concave sides (FIG. 4E), semi-circular (FIGS. 4B and 4F) and triangular (FIG. 4C). Additional examples of cross-sectional geometries for one or more portions of the frame 202 include, but are not limited to, circular, tubular, I-shaped, T-shaped, oval, and trapezoidal.



FIG. 3 provides an additional embodiment of frame 302 having different cross-sectional geometries along its length. For example, FIG. 3 provides an illustration in which the corner portions 314 of the frame 302, including the vertices 328, 330, 334 and 336, can have one or more of a round (e.g., circular, oval, and/or elliptical) cross-sectional geometry. As will be appreciated, each of the corner portions 314 of the frame 302 can themselves have similar and/or different cross-sectional geometries (e.g., corner portions 314 of vertices 328 and 330 could have a circular cross-sectional geometry, while the corner portions 314 of vertices 334 and 336 could have a elliptical or semi-elliptical cross-sectional geometry). Other combinations of cross-sectional geometries are possible.


In addition, FIG. 3 provides an illustration in which one or more of the intermediate portions 312 of the frame 302 can have different cross-sectional shapes along their length. For example, one or more of the members 320, 322, 324, and 326 can have a strip 342 geometry along a first length 351 and a second length 353 of the intermediate portion 312, and a round and/or semi-round (as discussed herein) 355 geometry along a third length 357 of the intermediate portion 312. As will be appreciated, various combinations of the cross-sectional geometries, as discussed herein, along the first, second, and third lengths 351, 353, and 357 are possible.


In addition to changes in cross-sectional geometry, there can also be changes in the widths 308 and/or the diameters of the round and/or semi-round geometries relative to each other along the length of the frame 302. Changes in shapes, cross-sectional geometries, widths and/or diameters can depend on many patient factors, including, but not limited to, where the valve 300 is to be implanted and the physiological environment in which the valve 300 is to be implanted.


As will be appreciated, the embodiments discussed herein are not intended to limit the present invention, as it is appreciated that other cross-sectional geometries and combinations thereof are also possible. As such, the present invention should not be limited to the illustration of the frame 102 in FIG. 1, the frame 202 in FIG. 2 and/or frame 302 in FIG. 3. In addition, transitions from one cross-sectional geometry to another cross-sectional geometry (e.g., from a round cross-sectional geometry to a ribbon cross-sectional geometry) can be created by mechanically deforming (e.g., with rollers or a press) the frame material. Other mechanisms for deforming the cross-sectional shape of the frame are also possible.


Referring again to FIGS. 1-3, the outer diameter 110, 210, and 310 and a length 143, 243, and 343 of valves 100, 200, and 300, respectively, can have a number of values. As will be appreciated, the outer diameter 110, 210, and 310 and the length 143, 243, and 343 of valves 100, 200, and 300, can each be determined based upon the location into which the valve 100, 200, and 300 is to be implanted.


Referring now to FIG. 1, the portions of frame 102 (e.g., the corner portions 114 and/or the intermediate portions 112) can further provide elastic regions for the frame 102. Typically, these elastic regions occur at portions of the frame 102 that include the curves and twists in the frame 102. The elastic regions allow the valve 100 to accommodate changes in body lumen size (e.g., diameter of the body lumen) by flexing to expand and/or contract to change the diameter of the frame 102. In one embodiment, the corner portions 114 and/or the intermediate portions 112 of the frame 102 can act as springs to allow the valve 100 to resiliently radially collapse and expand. The frame 102 can also provide sufficient contact and expansion force with the surface of a body lumen wall to encourage fixation of the valve 100 and to prevent retrograde flow within the body lumen around the edges of the frame 102 and the surface of a lumen when combined with a closed state of the valve leaflets (described in more detail below) attached thereto. Anchoring elements (e.g., barbs) can also be included with valve 100, as will be discussed herein.


The elastic regions of the frame 102 also allow valve 100 to elastically and repeatably travel between a collapsed state and an expanded state. FIGS. 5A and 5B provide an example of the valve 500 in a collapsed state (FIG. 5A) and in an expanded state (FIG. 5B). As shown in FIGS. 5A and 5B, the valve 500 can travel between the collapsed and the expanded state along a radial travel path 544 (as shown in FIG. 5B), where there can be a change in a cross sectional area 546 of lumen 505. For example, the valve frame 502 can travel along the radial travel path 544 so as to change a width 548 of lumen 505. This can allow the valve 500 to react appropriately to the distension and contraction of a body lumen in which the valve 500 is placed.


In addition to the illustrated corner portions 114, the elastic regions can further include, but are not limited to, other shapes for the valve frame 102 that allow for repeatable travel between the collapsed state and the expanded state. For example, the elastic regions can include integrated springs having a circular or an elliptical loop configuration. Other shapes are also possible.


The embodiments of the frame, such as frame 102 in FIG. 1, frame 202 in FIG. 2 and frame 302 in FIG. 3, can also be constructed of one or more of a number of materials and in a variety of configurations. Generally, the frame embodiments can have a unitary structure with an open frame configuration. The frame can also be self-expanding. Examples of self-expanding frames include those formed from temperature-sensitive memory alloy which changes shape at a designated temperature or temperature range. Alternatively, the self-expanding frames can include those having a spring-bias. In addition, the frame 102, 202, 302 can have a configuration that allows the frame embodiments be radially expandable through the use of a balloon catheter.


The materials used in constructing frame embodiments can also be pre- and post-treated. For example, the material characteristics of the frame can be modified by imparting to the corner portions, e.g. 114, 214 and 314, a radial arc that flares the frame outward from the longitudinal central axis. In one embodiment, the radial arc may be sufficiently large such that portions of the frame at the corners may extend beyond the outer diameter of the frame as defined by the first planar surface. Illustrations of such a radial arc, such as those described herein, can be found in co-pending U.S. patent application Ser. No. 11/150,331, filed on Jun. 10, 2005 and entitled “Venous Valve Frame, System, and Method”, which is incorporated herein by reference in its entirety.


The embodiments of the frame, such as frame 102 in FIG. 1, frame 202 in FIG. 2, and frame 302 in FIG. 3, can also be formed from one or more contiguous frame members. For example, the frame member of frame embodiments can be a single contiguous member. The single contiguous member can be bent around an elongate tubular mandrel to form the frame. The free ends of the single contiguous member can then be welded, fused, crimped, or otherwise joined together to form the frame. For example, the free ends of the single contiguous member could be joined through a butt joint. In addition, a joint could further include a collar, such as a segment of hypo tubing, place over and secured with the butt joint. In an additional embodiment, the frame member of frame can be derived (e.g., laser cut, water cut) from a single tubular segment. In an alternative embodiment, methods of joining the frame member to create the elastic region include, but are not limited to, welding, gluing, and fusing the frame member. The frame can be heat set by a method as is typically known for the material which forms the frame.


The frame embodiments can be formed from a number of materials. For example, the frame can be formed from a biocompatible metal, metal alloy, polymeric material, or combination thereof. As discussed herein, the frame can be self-expanding or balloon expandable. In addition, the frame can be configured so as to have the ability to move radially between the collapsed state and the expanded state. To accomplish this, the material used to form the frame should exhibit an elastic modulus and a yield stress that can accommodate large elastic strains and can recover from elastic deformations. Examples of suitable materials include, but are not limited to, medical grade stainless steel (e.g., 316L), titanium, tantalum, platinum alloys, niobium alloys, cobalt alloys, alginate, or combinations thereof. Additional frame embodiments may be formed from a shape-memory material, such as shape memory plastics, polymers, and thermoplastic materials which are inert in the body. Shaped memory alloys having superelastic properties generally made from ratios of nickel and titanium, commonly known as nitinol, are also possible materials. Other materials are also possible.


Frame can be expanded to provide a lumen (e.g., 105 in FIG. 1, 205 in FIG. 2, and 305 in FIG. 3) having a number of sizes. For example, the size of the lumen can be determined based upon the type of body lumen and the body lumen size in which the valve is to be placed. In an additional example, there can also be a minimum value for the width for the frame that ensures that the frame will have an appropriate expansion force against the inner wall of the body lumen in which the valve is being placed.


In one embodiment, the frame can further include one or more anchoring elements. For example, the one or more anchoring elements can include, but are not limited to, one or more barbs 150 projecting from the frame 102. The valve can further include one or more radiopaque markers (e.g., tabs, sleeves, welds, coatings such as formed by plating or dipping). For example, one or more portions of the frame can be formed from a radiopaque material. Radiopaque markers can be attached to and/or coated onto one or more locations along the frame. Examples of radiopaque material include, but are not limited to, gold, tantalum, and platinum. The position of the one or more radiopaque markers can be selected so as to provide information on the position, location and orientation of the valve during its implantation.


The embodiments of the valve further include the cover. In one embodiment, cover 104 can be located over at least the first planar surface 106 of the frame 102 so as to cover at least part of an outer surface 152 of the frame 102. For example, the cover 104 can extends over the outer surface 152 of the frame 102 so as to cover the outer surface 152 of the frame 102 thereby limiting, or eliminating, the exposure of the outer surface 152 of the frame 102.


In an additional example, the cover 104 can extend between each of the members 120, 122, 124, and 126 and vertices 128, 130, 134 and 136 to surround the circumference of the frame 102. Examples of are generally illustrated in FIGS. 1-3, 5 and 6. In an additional embodiment, the cover 104 can also be located over at least an inner surface 154 of the frame 102. A further embodiment includes the cover 104 located over at least the outer surface 152 and the inner surface 154. The cover 104 can further include surfaces defining a reversibly sealable opening 156 for unidirectional flow of a liquid through the lumen 105. For example, the surfaces of the cover 104 can be deflectable between a closed configuration in which fluid flow through the lumen 105 can be restricted and an open configuration in which fluid flow through the lumen 105 can be permitted.



FIGS. 6A-6D illustrate an additional embodiment of the venous valve 600. FIGS. 6A and 6B provide a perspective illustration of valve 600 in an open configuration (FIG. 6A) and a closed configuration (FIG. 6B). FIGS. 6C and 6D provide a sectional view taken along cut lines 6C-6C and 6D-6D shown in FIGS. 6A and 6B, respectively, to more clearly illustrate the embodiment of the venous valve 600.


As discussed herein, cover 604 includes surfaces defining the reversibly sealable opening 656 for unidirectional flow of a liquid through the lumen 605. For the embodiment illustrated in FIGS. 6A and 6B, the cover 604 extends over at least a portion of the frame 602 to a first connection point 658 and a second connection point 660 on the frame 602, as the same have been described and illustrated in connection with FIGS. 1-3. In one example, the first connection point 658 and the second connection point 660 can be located at the first vertex 628 and the second vertex 630 of the frame 602. The cover 604 extends between the first connection point 658 and the second connection point 660 to provide a first valve leaflet 662 and a second valve leaflet 664. The first valve leaflet 662 and the second valve leaflet 664 can form the reversibly sealable opening 656 extending between the first connection point 658 and the second connection point 660. So, for the example shown in FIG. 6A the first valve leaflet 662 and the second valve leaflet 664 form the reversibly sealable opening 656 extending between the first vertex 628 and the second vertex 630 of the frame 602.


As illustrated, the first valve leaflet 662 and the second valve leaflet 664 include a region 666 of the cover 604 that can move relative the frame 602. The region 666 of the cover 604 can be unbound (i.e., unsupported) by the frame 602 and extends between the first connection point 658 and the second connection point 660 of the valve 600. This configuration permits the reversibly sealable opening 656 to open and close in response to the fluid pressure differential across the valve leaflets 662 and 664.


For example, under antegrade fluid flow (i.e., positive fluid pressure) from a first end 668 towards a second end 670 of the valve 600, the first and second valve leaflets 662 and 664 can expand toward the inner surface 654 to create an opening through which fluid is permitted to move. In one example, the first valve leaflet 662 and the second valve leaflet 664 can each expand to define a semi-tubular structure when fluid opens the reversibly sealable opening 656. An example of the open configuration for the valve is shown in FIGS. 6A and 6C.


Under a retrograde fluid flow (i.e., negative fluid pressure) from the second end 670 towards the first end 668, the first and second valve leaflets 662 and 664 can move away from the inner surface 654 as the valve leaflets 662 and 664 begin to close valve 600. In one example, a pocket exists between the frame 602 and each of the first and second valve leaflets 662 and 664. The pocket allows fluid from the retrograde flow to develop pressure on a first major face 672 of the first and second valve leaflets 662 and 664, for example, as illustrated in FIG. 6D. As fluid pressure develops, the first and second valve leaflets 662 and 664 collapse, closing the reversibly sealable opening 656 to create a seal 674, thereby restricting retrograde fluid flow through the valve 600. In one example, the seal 674 can be created by the joining of a sealing surface 676 of the first and second valve leaflets 662 and 664, for example as illustrated in FIG. 6C. In the closed configuration, the first and second valve leaflets 662 and 664 can each have a concave structure when fluid closes the reversibly sealable opening 656. An example of a closed configuration for the valve is shown in FIGS. 6B and 6D.


Referring again to FIG. 1, valve 100 provides an embodiment in which the surfaces defining the reversibly sealable opening 156 provide a bi-leaflet configuration (i.e., a bicuspid valve) for valve 100. Although the embodiments in FIGS. 1, 2, 3 and 6A-6D illustrate and describe a bi-leaflet configuration for the valve of the present invention, designs employing a different number of valve leaflets (e.g., tri-leaflet valve) are possible. For example, additional connection points (e.g., three or more) could be used to provide additional valve leaflets (e.g., a tri-leaflet valve).


The first valve leaflet 162 and the second valve leaflet 164 can have a variety of sizes and shapes. For example, each of the first valve leaflet 162 and the second valve leaflet 164 can have a similar size and shape. In addition, each of the first valve leaflet 162 and the second valve leaflet 164 can include opposed first and second major surfaces 172 and 178, respectively. Each first major surface 172 of the first valve leaflet 162 and the second valve leaflet 164 can be oriented to face the second end 170 of valve 100.


Each of the first valve leaflet 162 and the second valve leaflet 164 can further provide the sealing surface 176 formed by portions of the first valve leaflet 162 and the second valve leaflet 164, where the sealing surface 176 can engage to define the closed configuration of valve 100. Sealing surface 176 of the first valve leaflet 162 and the second valve leaflet 164 can separate to provide for an open configuration of valve 100. In an additional example, each of the first valve leaflet 162 and the second valve leaflet 164 need not have a similar size and shape (i.e., the valve leaflets can have a different size and shape with respect to each other).


In one embodiment, each of the first valve leaflet 162 and the second valve leaflet 164 includes sufficient excess material spanning frame 102 such that fluid pressure (e.g., antegrade flow) acting on the second major surface 178 of the first valve leaflet 162 and the second valve leaflet 164 forces the valve 100 into an open configuration. The first valve leaflet 162 and the second valve leaflet 164 each further include an arcuate edge 180 positioned adjacent each other along a substantially catenary curve between the connection point 158 and the second connection point 160 in the closed configuration of valve 100. Similarly, the arcuate edge 180 can define opening 156 when the valve 100 is in the open configuration.


In an additional embodiment, in the open configuration the portion of the cover 104 forming the first valve leaflet 162 and the second valve leaflet 164 provides sufficient excess material spanning between the first connection point 158 and the second connection point 160 to allow the first and second major surfaces 172 and 178 to take on a semi-tubular structure 182, as shown in FIG. 1, when fluid pressure opens the valve 100. In an additional embodiment, the arcuate edges 180 of valve 100 can open to approximately the full inner diameter of a body lumen.


Each of the second major surfaces 178 of the first valve leaflet 162 and the second valve leaflet 164 can further include a curve imparted thereto so as to provide the first major surface 172 with the concave structure. The concave structure allows the first valve leaflet 162 and the second valve leaflet 164 to better collect retrograde fluid flow to urge the first valve leaflet 162 and the second valve leaflet 164 towards the closed configuration. For example, as retrograde flow begins, the first valve leaflet 162 and the second valve leaflet 164 respond by moving towards the center (e.g., towards 118) of valve 100. As the first valve leaflet 162 and the second valve leaflet 164 approach the center of the device the sealing surfaces 176 make sufficient contact to effectively close valve 100 and restrict retrograde fluid flow.


In an additional embodiment, the first valve leaflet 162 and the second valve leaflet 164 can include one or more support structures, where the support structures can be integrated into and/or onto the valve leaflets 162 and 164. For example, the first valve leaflet 162 and the second valve leaflet 164 can include one or more support ribs, as the same will be known and understood, having a predetermined shape. In one embodiment, the predetermined shape of the support ribs can include a curved bias so as to provide the first valve leaflet 162 and the second valve leaflet 164 with a curved configuration. Support ribs can be constructed of a flexible material and have dimensions (e.g., thickness, width and length) and cross-sectional shape that allows the support ribs to be flexible when the first valve leaflet 162 and the second valve leaflet 164 are urged into an open position, and stiff when the first valve leaflet 162 and the second valve leaflet 164 are urged into a closed position upon experiencing sufficient back flow pressure from the direction downstream from the valve. In an additional embodiment, support ribs can also be attached to valve frame 102 so as to impart a spring bias to the valve leaflets in either the open or the closed configuration.


In one embodiment, the material of the first valve leaflet 162 and the second valve leaflet 164 can be sufficiently thin and pliable so as to permit radially-collapsing of the valve leaflets for delivery by catheter to a location within a body lumen. The first valve leaflet 162 and the second valve leaflet 164 can be constructed of a fluid-impermeable biocompatible material that can be either synthetic or biologic. Possible synthetic materials include, but are not limited to, expanded polytetrafluoroethylene (ePTFE), polytetrafluoroethylene (PTFE), polystyrene-polyisobutylene-polystyrene (SIBS), polyurethane, segmented poly(carbonate-urethane), Dacron, polyethlylene (PE), polyethylene terephthalate (PET), silk, urethane, Rayon, Silicone, or the like. Possible biologic materials include, but are not limited to, autologous, allogeneic or xenograft material. These include explanted veins and decellularized basement membrane materials, such as small intestine submucosa (SIS) or umbilical vein.


As discussed herein, the cover 104 can be located over at least the outer surface 152 of the frame 102. In an additional embodiment, the cover 104 can also be located over at least the inner surface 154 of the frame 102, where the cover 104 can be joined to itself in the area between the members (e.g., between first member 120 and third member 124, and second member 122 and fourth member 128) so as to fully or partially encase the frame 102. Numerous techniques may be employed to laminate or bond cover 104 on the outer surface 152 and/or the inner surface 154 of the frame 102, including heat setting, adhesive welding, application of uniform force and other bonding techniques. Additionally, the cover 104 may be folded over the first end of the frame 102 to provide the cover 104 on both the outer surface 106 and the inner surface 108. Cover 104 can also be joined to itself and/or the members according to the methods described in U.S. Patent Application Publication US 2002/0178570 to Sogard et al., which is hereby incorporated by reference in its entirety.


The cover 104 can also be coupled to the connection points so as to form the valve leaflets, as discussed herein. In one embodiment, the cover 104 can be in the form of a sheet or a sleeve of material, as discussed herein, which can be connected to the frame 102. Alternatively, the cover 104 can initially be in the form of a liquid that can be used to cast and/or form the cover over the frame 102. Other forms, including intermediate forms, of the cover 104 are also possible.


The cover 104 can be coupled to the frame 102, including the connection points 158 and 160, in a variety of ways so as to provide the various embodiments of the valve of the present invention. For example, a variety of fasteners can be used to couple the cover 104 to the frame 102 so as to form the valve 100. Suitable fasteners can include, but are not limited to, biocompatible staples, glues, sutures or combinations thereof. In an additional embodiment, the cover 104 can be coupled to the frame 102 through the use of heat sealing, solvent bonding, adhesive bonding, or welding cover 104 to either a portion of the cover 104 (i.e., itself) and/or the frame 102.


The cover 104, including the valve leaflets 162 and 164, may also be treated and/or coated with a number of surface or material treatments. For example, the cover 104 can be treated with one or more biologically active compounds and/or materials that may promote and/or inhibit endothelization and/or smooth muscle cell growth of the cover 104, including the valve leaflets 162 and 164. Similarly, the cover 104 may be seeded and covered with cultured tissue cells (e.g., endothelial cells) derived from a either a donor or the host patient which are attached to the valve leaflets 162 and 164. The cultured tissue cells may be initially positioned to extend either partially or fully over the valve leaflets 162 and 164.


Cover 104, in addition to forming valve leaflets 162 and 164, can also be capable of inhibiting thrombus formation. Additionally, cover 104 may either prevent or facilitate tissue ingrowth therethrough, as the particular application for the valve 100 may dictate. For example, cover 104 on the outer surface 152 may be formed from a porous material to facilitate tissue ingrowth therethrough, while cover 104 on the inner surface 154 may be formed from a material or a treated material which inhibits tissue ingrowth.



FIG. 7 illustrates one embodiment of a system 784. System 784 includes valve 700, as described herein, reversibly joined to catheter 786. The catheter 786 includes an elongate body 788 having a proximal end 790 and a distal end 792, where valve 700 can be located between the proximal end 790 and distal end 792. The catheter 786 can further include a lumen 794 longitudinally extending to the distal end 792. In one embodiment, lumen 794 extends between proximal end 790 and distal end 792 of catheter 786. The catheter 786 can further include a guidewire lumen 796 that extends within the elongate body 788, where the guidewire lumen 796 can receive a guidewire for positioning the catheter 786 and the valve 700 within a body lumen (e.g., a vein of a patient).


The system 784 can further include a deployment shaft 798 positioned within lumen 794, and a sheath 701 positioned adjacent the distal end 792. In one embodiment, the valve 700 can be positioned at least partially within the sheath 601 and adjacent the deployment shaft 798. The deployment shaft 798 can be moved within the lumen 794 to deploy valve 700. For example, deployment shaft 798 can be used to push valve 700 from sheath 701 in deploying valve 700.



FIG. 8 illustrates an additional embodiment of the system 884. The catheter 886 includes elongate body 888, lumen 894, a retraction system 803 and a retractable sheath 809. The retractable sheath 809 can be positioned over at least a portion of the elongate body 888, where the retractable sheath 809 can move longitudinally along the elongate body 888. The valve 800 can be positioned at least partially within the retractable sheath 809, where the retractable sheath 809 moves along the elongate body 888 to deploy the valve 800. In one embodiment, retraction system 803 includes one or more wires 895 coupled to the retractable sheath 809, where the wires are positioned at least partially within and extend through lumen 894 in the elongate body 888. Wires of the retraction system 803 can then be used to retract the retractable sheath 809 in deploying valve 800.



FIG. 9 illustrates an additional embodiment of the system 984. The catheter 986 includes elongate body 988, an inflatable balloon 915 positioned adjacent the distal end 992, and a lumen 917 longitudinally extending in the elongate body 988 of the catheter 986 from the inflatable balloon 915 to the proximal end 990. In the present example, the inflatable balloon 915 can be at least partially positioned within the lumen 905 of the valve 900. The inflatable balloon 915 can be inflated through the lumen 917 to deploy the valve 900.


The embodiments of the present invention further include methods for forming the valve of the present invention, as discussed herein. For example, the valve can be formed from the frame and the cover over at least the outer surface of the frame, where the cover includes surfaces defining the reversibly sealable opening for unidirectional flow of a liquid through the lumen. In an additional example, the valve can be reversibly joined to the catheter, which can include a process of altering the shape of the valve from a first shape, for example an expanded state, to the compressed state, as described herein.


For example, the valve can be reversibly joined with the catheter by positioning valve in the compressed state at least partially within the sheath of the catheter. In one embodiment, positioning the valve at least partially within the sheath of the catheter includes positioning the valve in the compressed state adjacent the deployment shaft of the catheter. In an another embodiment, the sheath of the catheter functions as a retractable sheath, where the valve in the compressed state can be reversibly joined with the catheter by positioning the valve at least partially within the reversible sheath of the catheter. In a further embodiment, the catheter can include an inflatable balloon, where the balloon can be positioned at least partially within the lumen of the valve, for example, in its compressed state.


The embodiments of the valve described herein may be used to replace, supplement, or augment valve structures within one or more lumens of the body. For example, embodiments of the present invention may be used to replace an incompetent venous valve and help to decrease backflow of blood in the venous system of the legs.


In one embodiment, the method of replacing, supplementing, and/or augmenting a valve structure can include positioning at least part of the catheter including the valve at a predetermined location within the lumen of a body. For example, the predetermined location can include a position within a body lumen of a venous system of a patient, such as a vein of a leg.


In one embodiment, positioning the catheter that includes the valve within the body lumen of a venous system includes introducing the catheter into the venous system of the patient using minimally invasive percutaneous, transluminal catheter based delivery system, as is known in the art. For example, a guidewire can be positioned within a body lumen of a patient that includes the predetermined location. The catheter, including valve, as described herein, can be positioned over the guidewire and the catheter advanced so as to position the valve at or adjacent the predetermined location. In one embodiment, radiopaque markers on the catheter and/or the valve, as described herein, can be used to help locate and position the valve. For example, embodiments for positioning radiopaque markers on the catheter and/or the valve can be found in co-pending U.S. patent application Ser. No. 11/150,331, filed on Jun. 10, 2005 and entitled “Venous Valve Frame, System, and Method”, which is incorporated herein by reference in its entirety.


The valve can be deployed from the catheter at the predetermined location in a number of ways, as described herein. In one embodiment, valve of the present invention can be deployed and placed in a number of vascular locations. For example, valve can be deployed and placed within a major vein of a patient's leg. In one embodiment, major veins include, but are not limited to, those of the peripheral venous system. Examples of veins in the peripheral venous system include, but are not limited to, the superficial veins such as the short saphenous vein and the greater saphenous vein, and the veins of the deep venous system, such as the popliteal vein and the femoral vein.


As discussed herein, the valve can be deployed from the catheter in a number of ways. For example, the catheter can include the retractable sheath in which valve can be at least partially housed, as discussed herein. Valve can be deployed by retracting the retractable sheath of the catheter, where the valve self-expands to be positioned at the predetermined location. In an additional example, the catheter can include a deployment shaft and sheath in which valve can be at least partially housed adjacent the deployment shaft, as discussed herein. Valve can be deployed by moving the deployment shaft through the catheter to deploy valve from the sheath, where the valve self-expands to be positioned at the predetermined location. In an additional embodiment, the valve can be deployed through the use of an inflatable balloon.


Once implanted, the valve can provide sufficient contact and expansion force against the body lumen wall to prevent retrograde flow between the valve and the body lumen wall. For example, the valve can be selected to have a larger expansion diameter than the diameter of the inner wall of the body lumen. This can then allow valve to exert a force on the body lumen wall and accommodate changes in the body lumen diameter, while maintaining the proper placement of valve. As described herein, the valve can engage the lumen so as to reduce the volume of retrograde flow through and around valve. It is, however, understood that some leaking or fluid flow may occur between the valve and the body lumen and/or through valve leaflets.


While the present invention has been shown and described in detail above, it will be clear to the person skilled in the art that changes and modifications may be made without departing from the scope of the invention. As such, that which is set forth in the foregoing description and accompanying drawings is offered by way of illustration only and not as a limitation. The actual scope of the invention is intended to be defined by the following claims, along with the full range of equivalents to which such claims are entitled.


In addition, one of ordinary skill in the art will appreciate upon reading and understanding this disclosure that other variations for the invention described herein can be included within the scope of the present invention. For example, the frame 102 and/or the cover 104 can be coated with a non-thrombogenic biocompatible material, as are known or will be known.


In the foregoing Detailed Description, various features are grouped together in several embodiments for the purpose of streamlining the disclosure. This method of disclosure is not to be interpreted as reflecting an intention that the embodiments of the invention require more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive subject matter lies in less than all features of a single disclosed embodiment. Thus, the following claims are hereby incorporated into the Detailed Description, with each claim standing on its own as a separate embodiment.

Claims
  • 1. A venous valve, comprising: a frame having corner portions that provide a spring force to counter radial compression of the frame and with intermediate portions therebetween, the intermediate portions having a cross-sectional geometry including at least a first planar surface of a predetermined width, where each intermediate portion is twisted about three fourths of a revolution into at least a partial helical configuration and does not intersect with any other intermediate portions, and the corner portions form a first vertex and a second vertex relative a first end of the frame, a third vertex and a fourth vertex at the first end of the frame relative the first and second vertex, where the first vertex and the second vertex are positioned opposite each other along a common axis; anda cover on the frame, wherein the cover includes surfaces defining a reversibly sealable opening for unidirectional flow of a liquid through the valve.
  • 2. The venous valve of claim 1, wherein the cross-sectional geometry of intermediate portions of the frame includes a second planar surface parallel with the first planar surface.
  • 3. The venous valve of claim 2, wherein the first planar surface has an essentially symmetrical relation to an outer diameter of the frame.
  • 4. The venous valve of claim 1, wherein the cover extends to at least the first vertex and the second vertex to form a first valve leaflet and a second valve leaflet between the first vertex and the second vertex.
  • 5. The venous valve of claim 4, wherein the first valve leaflet and the second valve leaflet form the reversibly sealable opening extending between the first vertex and the second vertex.
  • 6. The venous valve of claim 1, wherein the at least partial helical configuration imparts a radially expansion force when the frame is radially compressed.
  • 7. The venous valve of claim 1, wherein the cover on the frame includes the cover over an outer surface of the frame.
  • 8. A method, comprising: positioning at least part of a catheter including a venous valve at a predetermined location, wherein the venous valve includes: a frame having corner portions that provide a spring force to counter radial compression of the frame with intermediate portions therebetween, the intermediate portions having a cross-sectional geometry including at least a first planar surface of a predetermined width, where each intermediate portion is twisted about three quarters of a revolution into at least a partial helical configuration and does not intersect with any other intermediate portions, and the corner portions form a first vertex and a second vertex relative a first end of the frame, a third vertex and a fourth vertex at the first end of the frame relative the first and second vertex, where the first vertex and the second vertex are positioned opposite each other along a common axis;a cover on the frame, wherein the cover includes surfaces defining a reversibly scalable opening for unidirectional flow of a liquid through the valve; anddeploying the venous valve from the catheter at the predetermined location.
  • 9. The method of claim 8, wherein the cover on the frame extends to at least the first vertex and the second vertex to form a first valve leaflet and a second valve leaflet between the first vertex and the second vertex, wherein the first valve leaflet and the second valve leaflet form the reversibly sealable opening extending between the first vertex and the second vertex.
  • 10. The method of claim 8, wherein positioning at least part of the catheter at the predetermined location includes positioning at least part of the catheter within a vein of a leg.
  • 11. The method of claim 8, wherein the catheter includes a retractable sheath, the venous valve at least partially housed within the retractable sheath, and deploying the venous valve from the catheter at the predetermined location includes retracting the retractable sheath of the catheter.
  • 12. The method of claim 8, wherein the catheter includes a deployment shaft and a sheath, the venous valve at least partially housed within the sheath adjacent the deployment shaft, and deploying the venous valve from the catheter at the predetermined location includes moving the deployment shaft to deploy the venous valve from the sheath of the catheter.
  • 13. The method of claim 8, wherein the cross-sectional geometry of intermediate portions of the frame includes a second planar surface parallel with the first planar surface; and the cover extending to at least the first vertex and the second vertex to form a first valve leaflet and a second valve leaflet between the first vertex and the second vertex, wherein the first valve leaflet and the second valve leaflet includes a surface defining a reversibly sealable opening for unidirectional flow of a liquid through the lumen.
  • 14. The method of claim 8, wherein the catheter includes an inflatable balloon, the inflatable balloon at least partially positioned within the lumen of the venous valve; and deploying the venous valve includes inflating the balloon to deploy the vascular valve.
US Referenced Citations (626)
Number Name Date Kind
3671979 Moulopoulos Jun 1972 A
4291420 Reul Sep 1981 A
4787901 Baykut Nov 1988 A
4872874 Taheri Oct 1989 A
4935030 Alonso Jun 1990 A
4994077 Dobben Feb 1991 A
5002567 Bona et al. Mar 1991 A
5141491 Bowald Aug 1992 A
5163953 Vince Nov 1992 A
5219355 Parodi et al. Jun 1993 A
5254127 Wholey et al. Oct 1993 A
5327774 Nguyen et al. Jul 1994 A
5332402 Teitelbaum Jul 1994 A
5370685 Stevens Dec 1994 A
5411552 Anderson et al. May 1995 A
5469868 Reger Nov 1995 A
5480423 Ravenscroft et al. Jan 1996 A
5500014 Quijano et al. Mar 1996 A
5545214 Stevens Aug 1996 A
5554185 Block et al. Sep 1996 A
5643208 Parodi Jul 1997 A
5693087 Parodi Dec 1997 A
5713953 Vallana et al. Feb 1998 A
5716370 Williamson, IV et al. Feb 1998 A
5735859 Fischell et al. Apr 1998 A
5741326 Solovay Apr 1998 A
5741333 Frid Apr 1998 A
5800506 Perouse Sep 1998 A
5824061 Quijano et al. Oct 1998 A
5879320 Cazenave Mar 1999 A
5895419 Tweden et al. Apr 1999 A
5910170 Reimink et al. Jun 1999 A
6010531 Donlon et al. Jan 2000 A
6042607 Williamson, IV et al. Mar 2000 A
6139575 Shu et al. Oct 2000 A
6287334 Moll et al. Sep 2001 B1
6312447 Grimes Nov 2001 B1
6355030 Aldrich et al. Mar 2002 B1
6402780 Williamson, IV et al. Jun 2002 B2
6419696 Ortiz et al. Jul 2002 B1
6425916 Garrison et al. Jul 2002 B1
6440164 DiMatteo et al. Aug 2002 B1
6451054 Stevens Sep 2002 B1
6454799 Schreck Sep 2002 B1
6461366 Seguin Oct 2002 B1
6503272 Duerig et al. Jan 2003 B2
6508833 Pavcnik et al. Jan 2003 B2
6564805 Garrison et al. May 2003 B2
6569196 Vesely May 2003 B1
6602286 Strecker Aug 2003 B1
6629534 St. Goar et al. Oct 2003 B1
6635085 Caffey et al. Oct 2003 B1
6666885 Moe Dec 2003 B2
6666886 Tranquillo et al. Dec 2003 B1
6669725 Scott Dec 2003 B2
6673109 Cox Jan 2004 B2
6676698 McGuckin, Jr. et al. Jan 2004 B2
6676702 Mathis Jan 2004 B2
6682558 Tu et al. Jan 2004 B2
6682559 Myers et al. Jan 2004 B2
6685739 DiMatteo et al. Feb 2004 B2
6692512 Jang Feb 2004 B2
6695866 Kuehn et al. Feb 2004 B1
6695878 McGuckin, Jr. et al. Feb 2004 B2
6709456 Langberg et al. Mar 2004 B2
6709457 Otte et al. Mar 2004 B1
6716241 Wilder et al. Apr 2004 B2
6716244 Klaco Apr 2004 B2
6719767 Kimblad Apr 2004 B1
6719784 Henderson Apr 2004 B2
6719786 Ryan et al. Apr 2004 B2
6719787 Cox Apr 2004 B2
6719788 Cox Apr 2004 B2
6719789 Cox Apr 2004 B2
6719790 Brendzel et al. Apr 2004 B2
6723038 Schroeder et al. Apr 2004 B1
6723122 Yang et al. Apr 2004 B2
6723123 Kazatchkov et al. Apr 2004 B1
6726715 Sutherland Apr 2004 B2
6726716 Marquez Apr 2004 B2
6726717 Alfieri et al. Apr 2004 B2
6730118 Spenser et al. May 2004 B2
6730121 Ortiz et al. May 2004 B2
6730122 Pan et al. May 2004 B1
6736845 Marquez et al. May 2004 B2
6736846 Cox May 2004 B2
6749630 McCarthy et al. Jun 2004 B2
6752813 Goldfarb et al. Jun 2004 B2
6752828 Thornton Jun 2004 B2
6755857 Peterson et al. Jun 2004 B2
6761734 Suhr Jul 2004 B2
6761735 Eberhardt et al. Jul 2004 B2
6764494 Menz et al. Jul 2004 B2
6764508 Roehe et al. Jul 2004 B1
6764509 Chinn et al. Jul 2004 B2
6764510 Vidlund et al. Jul 2004 B2
6767362 Schreck Jul 2004 B2
6769434 Liddicoat et al. Aug 2004 B2
6770083 Seguin Aug 2004 B2
6780200 Jansen Aug 2004 B2
6786924 Ryan et al. Sep 2004 B2
6786925 Schoon et al. Sep 2004 B1
6790229 Berreklouw Sep 2004 B1
6790230 Beyersdorf et al. Sep 2004 B2
6790231 Liddicoat et al. Sep 2004 B2
6793673 Kowalsky et al. Sep 2004 B2
6797000 Simpson et al. Sep 2004 B2
6797001 Mathis et al. Sep 2004 B2
6797002 Spence et al. Sep 2004 B2
6802860 Cosgrove et al. Oct 2004 B2
6805710 Bolling et al. Oct 2004 B2
6805711 Quijano et al. Oct 2004 B2
6810882 Langberg et al. Nov 2004 B2
6821297 Snyders Nov 2004 B2
6824562 Mathis et al. Nov 2004 B2
6830584 Seguin Dec 2004 B1
6830585 Artof et al. Dec 2004 B1
6837902 Nguyen et al. Jan 2005 B2
6840246 Downing Jan 2005 B2
6840957 DiMatteo et al. Jan 2005 B2
6846324 Stobie Jan 2005 B2
6846325 Liddicoat Jan 2005 B2
6858039 McCarthy Feb 2005 B2
6869444 Gabbay Mar 2005 B2
6872226 Cali et al. Mar 2005 B2
6875224 Grimes Apr 2005 B2
6875230 Morita et al. Apr 2005 B1
6875231 Anduiza et al. Apr 2005 B2
6881199 Wilk et al. Apr 2005 B2
6881224 Kruse et al. Apr 2005 B2
6883522 Spence et al. Apr 2005 B2
6890352 Lentell May 2005 B1
6890353 Cohn et al. May 2005 B2
6893459 Macoviak May 2005 B1
6893460 Spenser et al. May 2005 B2
6896700 Lu et al. May 2005 B2
6902576 Drasler et al. Jun 2005 B2
6908478 Alferness et al. Jun 2005 B2
6908481 Cribier Jun 2005 B2
6911043 Myers et al. Jun 2005 B2
6913608 Liddicoat et al. Jul 2005 B2
6916338 Speziali Jul 2005 B2
6918917 Nguyen et al. Jul 2005 B1
6921407 Nguyen et al. Jul 2005 B2
6921811 Zamora et al. Jul 2005 B2
6926715 Hauck et al. Aug 2005 B1
6926730 Nguyen et al. Aug 2005 B1
6929653 Strecter Aug 2005 B2
6932838 Schwartz et al. Aug 2005 B2
6936067 Buchanan Aug 2005 B2
6939359 Tu et al. Sep 2005 B2
6942694 Liddicoat et al. Sep 2005 B2
6945957 Freyman Sep 2005 B2
6945978 Hyde Sep 2005 B1
6945996 Sedransk Sep 2005 B2
6945997 Huynh et al. Sep 2005 B2
6949122 Adams et al. Sep 2005 B2
6951571 Srivastava Oct 2005 B1
6951573 Dilling Oct 2005 B1
6953332 Kurk et al. Oct 2005 B1
6955689 Ryan et al. Oct 2005 B2
6958076 Acosta et al. Oct 2005 B2
6962605 Cosgrove et al. Nov 2005 B2
6964682 Nguyen-Thien-Nhon et al. Nov 2005 B2
6964683 Kowalsky et al. Nov 2005 B2
6964684 Ortiz et al. Nov 2005 B2
6966925 Stobie Nov 2005 B2
6966926 Mathis Nov 2005 B2
6974464 Quijano et al. Dec 2005 B2
6974474 Pavcnik et al. Dec 2005 B2
6974476 McGuckin, Jr. et al. Dec 2005 B2
6976995 Mathis et al. Dec 2005 B2
6979350 Moll et al. Dec 2005 B2
6986775 Morales et al. Jan 2006 B2
6989027 Allen et al. Jan 2006 B2
6989028 Lashinski et al. Jan 2006 B2
6997950 Chawla Feb 2006 B2
6997951 Solem et al. Feb 2006 B2
7004176 Lau Feb 2006 B2
7007396 Rudko et al. Mar 2006 B2
7011669 Kimblad Mar 2006 B2
7011681 Vesely Mar 2006 B2
7011682 Lahsinski et al. Mar 2006 B2
7018406 Seguin et al. Mar 2006 B2
7018407 Wright et al. Mar 2006 B1
7018408 Bailey et al. Mar 2006 B2
7022134 Quijano et al. Apr 2006 B1
7025780 Gabbay Apr 2006 B2
7033390 Johnson et al. Apr 2006 B2
7037333 Myers et al. May 2006 B2
7037334 Hlavka et al. May 2006 B1
7041128 McGuckin, Jr. et al. May 2006 B2
7041132 Quijano et al. May 2006 B2
7044966 Svanidze et al. May 2006 B2
7044967 Solem et al. May 2006 B1
7048754 Martin et al. May 2006 B2
7048757 Shaknovich May 2006 B2
7052487 Cohn et al. May 2006 B2
7052507 Wakuda et al. May 2006 B2
7063722 Marquez Jun 2006 B2
7066954 Ryan et al. Jun 2006 B2
7070616 Majercak et al. Jul 2006 B2
7070618 Streeter Jul 2006 B2
7077862 Vidlund et al. Jul 2006 B2
7081131 Thornton Jul 2006 B2
7087064 Hyde Aug 2006 B1
7089051 Jäverud et al. Aug 2006 B2
7090695 Solem et al. Aug 2006 B2
20020013571 Goldfarb et al. Jan 2002 A1
20020026216 Grimes Feb 2002 A1
20020082630 Menz et al. Jun 2002 A1
20020099439 Schwartz et al. Jul 2002 A1
20020123802 Snyders Sep 2002 A1
20020151970 Garrison et al. Oct 2002 A1
20020183835 Taylor et al. Dec 2002 A1
20020183838 Liddicoat et al. Dec 2002 A1
20020198594 Schreck Dec 2002 A1
20030050694 Yang et al. Mar 2003 A1
20030130729 Paniagua et al. Jul 2003 A1
20030163194 Quijano et al. Aug 2003 A1
20030167071 Martin et al. Sep 2003 A1
20030171806 Mathis et al. Sep 2003 A1
20030199975 Gabbay Oct 2003 A1
20030229394 Ogle et al. Dec 2003 A1
20030229395 Cox Dec 2003 A1
20030233142 Morales et al. Dec 2003 A1
20030236568 Hojeibane et al. Dec 2003 A1
20030236569 Mathis et al. Dec 2003 A1
20040002719 Oz et al. Jan 2004 A1
20040003819 St. Goar et al. Jan 2004 A1
20040010305 Alferness et al. Jan 2004 A1
20040015230 Moll et al. Jan 2004 A1
20040015232 Shu et al. Jan 2004 A1
20040015233 Jansen Jan 2004 A1
20040019374 Hojeibane et al. Jan 2004 A1
20040019377 Taylor et al. Jan 2004 A1
20040019378 Hlavka et al. Jan 2004 A1
20040024447 Haverich Feb 2004 A1
20040024451 Johnson et al. Feb 2004 A1
20040024452 Kruse et al. Feb 2004 A1
20040030321 Fangrow, Jr. Feb 2004 A1
20040030381 Shu Feb 2004 A1
20040030382 St. Goar et al. Feb 2004 A1
20040030405 Carpentier et al. Feb 2004 A1
20040034380 Woolfson et al. Feb 2004 A1
20040034411 Quijano et al. Feb 2004 A1
20040039436 Spenser et al. Feb 2004 A1
20040039442 St. Goar et al. Feb 2004 A1
20040039443 Solem et al. Feb 2004 A1
20040044350 Martin et al. Mar 2004 A1
20040044365 Bachman Mar 2004 A1
20040044403 Bischoff et al. Mar 2004 A1
20040049207 Goldfarb et al. Mar 2004 A1
20040049211 Tremulis et al. Mar 2004 A1
20040049266 Anduiza et al. Mar 2004 A1
20040059351 Eigler et al. Mar 2004 A1
20040059411 Strecker Mar 2004 A1
20040059412 Lytle, IV et al. Mar 2004 A1
20040060161 Leal et al. Apr 2004 A1
20040073301 Donlon et al. Apr 2004 A1
20040073302 Rourke et al. Apr 2004 A1
20040078072 Tu et al. Apr 2004 A1
20040078074 Anderson et al. Apr 2004 A1
20040082910 Constantz et al. Apr 2004 A1
20040082923 Field Apr 2004 A1
20040082991 Nguyen et al. Apr 2004 A1
20040087975 Lucatero et al. May 2004 A1
20040088045 Cox May 2004 A1
20040088046 Speziali May 2004 A1
20040092858 Wilson et al. May 2004 A1
20040093060 Seguin et al. May 2004 A1
20040093070 Hojeibane et al. May 2004 A1
20040093080 Helmus et al. May 2004 A1
20040097979 Svanidze et al. May 2004 A1
20040098098 McGuckin, Jr. et al. May 2004 A1
20040098112 DiMatteo et al. May 2004 A1
20040102839 Cohn et al. May 2004 A1
20040102840 Solem et al. May 2004 A1
20040102842 Jansen May 2004 A1
20040106976 Bailey et al. Jun 2004 A1
20040106990 Spence et al. Jun 2004 A1
20040106991 Hopkins et al. Jun 2004 A1
20040111096 Tu et al. Jun 2004 A1
20040117009 Cali et al. Jun 2004 A1
20040122448 Levine Jun 2004 A1
20040122512 Navia et al. Jun 2004 A1
20040122513 Navia et al. Jun 2004 A1
20040122514 Fogarty et al. Jun 2004 A1
20040122515 Chu Jun 2004 A1
20040122516 Fogarty et al. Jun 2004 A1
20040127979 Wilson et al. Jul 2004 A1
20040127980 Kowalsky et al. Jul 2004 A1
20040127981 Rahdert et al. Jul 2004 A1
20040127982 Machold et al. Jul 2004 A1
20040133220 Lashinski et al. Jul 2004 A1
20040133267 Lane Jul 2004 A1
20040133273 Cox Jul 2004 A1
20040138742 Myers et al. Jul 2004 A1
20040138743 Myers et al. Jul 2004 A1
20040138744 Lashinski et al. Jul 2004 A1
20040138745 Macoviak et al. Jul 2004 A1
20040148018 Carpentier et al. Jul 2004 A1
20040148019 Vidlund et al. Jul 2004 A1
20040148020 Vidlund et al. Jul 2004 A1
20040153052 Mathis Aug 2004 A1
20040153146 Lashinski et al. Aug 2004 A1
20040153147 Mathis Aug 2004 A1
20040158321 Reuter et al. Aug 2004 A1
20040162610 Liska et al. Aug 2004 A1
20040167539 Keuhn et al. Aug 2004 A1
20040167620 Ortiz et al. Aug 2004 A1
20040172046 Hlavka et al. Sep 2004 A1
20040176839 Huynh et al. Sep 2004 A1
20040176840 Langberg et al. Sep 2004 A1
20040181238 Zarbatany et al. Sep 2004 A1
20040186444 Daly et al. Sep 2004 A1
20040186558 Pavcnik et al. Sep 2004 A1
20040186561 McGuckin, Jr. et al. Sep 2004 A1
20040186563 Lobbi Sep 2004 A1
20040186565 Schreck Sep 2004 A1
20040186566 Hindrichs et al. Sep 2004 A1
20040193191 Starksen et al. Sep 2004 A1
20040193253 Thorpe et al. Sep 2004 A1
20040193260 Alferness et al. Sep 2004 A1
20040199155 Mollenauer Oct 2004 A1
20040199183 Oz et al. Oct 2004 A1
20040199191 Schwartz Oct 2004 A1
20040204758 Eberhardt et al. Oct 2004 A1
20040206363 McCarthy et al. Oct 2004 A1
20040210240 Saint Oct 2004 A1
20040210301 Obermiller Oct 2004 A1
20040210303 Sedransk Oct 2004 A1
20040210304 Seguin et al. Oct 2004 A1
20040210305 Shu et al. Oct 2004 A1
20040210306 Quijano et al. Oct 2004 A1
20040210307 Khairkhahan Oct 2004 A1
20040215333 Duran et al. Oct 2004 A1
20040215339 Drasler et al. Oct 2004 A1
20040220654 Mathis et al. Nov 2004 A1
20040220657 Nieminen et al. Nov 2004 A1
20040225322 Garrison et al. Nov 2004 A1
20040225344 Hoffa et al. Nov 2004 A1
20040225348 Case et al. Nov 2004 A1
20040225352 Osborne et al. Nov 2004 A1
20040225353 McGuckin, Jr. et al. Nov 2004 A1
20040225354 Allen et al. Nov 2004 A1
20040225355 Stevens Nov 2004 A1
20040225356 Frater Nov 2004 A1
20040230117 Tosaya et al. Nov 2004 A1
20040230297 Thornton Nov 2004 A1
20040236411 Sarac et al. Nov 2004 A1
20040236418 Stevens Nov 2004 A1
20040236419 Milo Nov 2004 A1
20040243153 Liddicoat et al. Dec 2004 A1
20040243219 Fischer et al. Dec 2004 A1
20040243227 Starksen et al. Dec 2004 A1
20040243228 Kowalsky et al. Dec 2004 A1
20040243230 Navia et al. Dec 2004 A1
20040249452 Adams et al. Dec 2004 A1
20040254600 Zarbatany et al. Dec 2004 A1
20040254636 Flagle et al. Dec 2004 A1
20040260276 Rudko et al. Dec 2004 A1
20040260317 Bloom et al. Dec 2004 A1
20040260322 Rudko et al. Dec 2004 A1
20040260389 Case et al. Dec 2004 A1
20040260390 Sarac et al. Dec 2004 A1
20040260393 Rahdert et al. Dec 2004 A1
20040260394 Douk et al. Dec 2004 A1
20040267357 Allen et al. Dec 2004 A1
20050004583 Oz et al. Jan 2005 A1
20050004667 Swinford et al. Jan 2005 A1
20050010285 Lambrecht et al. Jan 2005 A1
20050010287 Macoviak et al. Jan 2005 A1
20050015112 Cohn et al. Jan 2005 A1
20050021056 St. Goar et al. Jan 2005 A1
20050021136 Xie et al. Jan 2005 A1
20050027261 Weaver et al. Feb 2005 A1
20050027348 Case et al. Feb 2005 A1
20050027351 Reuter et al. Feb 2005 A1
20050027353 Alferness et al. Feb 2005 A1
20050033398 Seguin Feb 2005 A1
20050033419 Alferness et al. Feb 2005 A1
20050033446 Deem et al. Feb 2005 A1
20050038506 Webler et al. Feb 2005 A1
20050038507 Alferness et al. Feb 2005 A1
20050043790 Seguin Feb 2005 A1
20050043792 Solem et al. Feb 2005 A1
20050049679 Taylor et al. Mar 2005 A1
20050049692 Numamoto et al. Mar 2005 A1
20050049696 Siess et al. Mar 2005 A1
20050049697 Sievers Mar 2005 A1
20050054977 Laird et al. Mar 2005 A1
20050055079 Duran Mar 2005 A1
20050055087 Starksen Mar 2005 A1
20050055088 Liddicoat et al. Mar 2005 A1
20050055089 Macoviak et al. Mar 2005 A1
20050060029 Le et al. Mar 2005 A1
20050060030 Lashinski et al. Mar 2005 A1
20050065460 Laird Mar 2005 A1
20050065550 Starksen et al. Mar 2005 A1
20050065594 Dimatteo et al. Mar 2005 A1
20050065597 Lansac Mar 2005 A1
20050070998 Rourke et al. Mar 2005 A1
20050075584 Cali Apr 2005 A1
20050075659 Realyvasquez et al. Apr 2005 A1
20050075662 Pedersen et al. Apr 2005 A1
20050075712 Biancucci et al. Apr 2005 A1
20050075713 Biancucci et al. Apr 2005 A1
20050075717 Nguyen et al. Apr 2005 A1
20050075718 Nguyen et al. Apr 2005 A1
20050075719 Bergheim Apr 2005 A1
20050075720 Nguyen et al. Apr 2005 A1
20050075723 Schroeder et al. Apr 2005 A1
20050075724 Svanidze et al. Apr 2005 A1
20050075725 Rowe Apr 2005 A1
20050075726 Svanidze et al. Apr 2005 A1
20050075728 Nguyen et al. Apr 2005 A1
20050075729 Nguyen et al. Apr 2005 A1
20050075730 Myers et al. Apr 2005 A1
20050075731 Artof et al. Apr 2005 A1
20050080483 Solem et al. Apr 2005 A1
20050085900 Case et al. Apr 2005 A1
20050085903 Lau Apr 2005 A1
20050085904 Lemmon Apr 2005 A1
20050090846 Pedersen et al. Apr 2005 A1
20050096735 Hojeibane et al. May 2005 A1
20050096738 Cali et al. May 2005 A1
20050096739 Cao May 2005 A1
20050096740 Langberg et al. May 2005 A1
20050101975 Nguyen et al. May 2005 A1
20050102026 Turner et al. May 2005 A1
20050107810 Morales et al. May 2005 A1
20050107811 Starksen et al. May 2005 A1
20050107812 Starksen et al. May 2005 A1
20050107872 Mensah et al. May 2005 A1
20050113910 Paniagua et al. May 2005 A1
20050119673 Gordon et al. Jun 2005 A1
20050119734 Spence et al. Jun 2005 A1
20050119735 Spence et al. Jun 2005 A1
20050125011 Spence et al. Jun 2005 A1
20050131438 Cohn Jun 2005 A1
20050137449 Nieminen et al. Jun 2005 A1
20050137450 Aronson et al. Jun 2005 A1
20050137451 Gordon et al. Jun 2005 A1
20050137676 Richardson et al. Jun 2005 A1
20050137681 Shoemaker et al. Jun 2005 A1
20050137682 Justino Jun 2005 A1
20050137685 Nieminen et al. Jun 2005 A1
20050137686 Salahieh et al. Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050137689 Salahieh et al. Jun 2005 A1
20050137690 Salahieh et al. Jun 2005 A1
20050137691 Salahieh et al. Jun 2005 A1
20050137692 Haug et al. Jun 2005 A1
20050137693 Haug et al. Jun 2005 A1
20050137694 Haug et al. Jun 2005 A1
20050137696 Salahieh et al. Jun 2005 A1
20050137697 Salahieh et al. Jun 2005 A1
20050137698 Salahieh et al. Jun 2005 A1
20050137699 Salahieh et al. Jun 2005 A1
20050137700 Spence et al. Jun 2005 A1
20050137701 Salahieh et al. Jun 2005 A1
20050137702 Haug et al. Jun 2005 A1
20050143807 Pavcnik et al. Jun 2005 A1
20050143809 Salahieh et al. Jun 2005 A1
20050143810 Dauner et al. Jun 2005 A1
20050143811 Realyvasquez Jun 2005 A1
20050149014 Hauck et al. Jul 2005 A1
20050149179 Mathis et al. Jul 2005 A1
20050149180 Mathis et al. Jul 2005 A1
20050149181 Eberhardt Jul 2005 A1
20050159810 Filsoufi Jul 2005 A1
20050159811 Lane Jul 2005 A1
20050165477 Anduiza et al. Jul 2005 A1
20050165478 Song Jul 2005 A1
20050171472 Lutter Aug 2005 A1
20050171601 Cosgrove et al. Aug 2005 A1
20050177227 Heim et al. Aug 2005 A1
20050177228 Solem et al. Aug 2005 A1
20050182483 Osborne et al. Aug 2005 A1
20050184122 Hlavka et al. Aug 2005 A1
20050187614 Agnew Aug 2005 A1
20050187616 Realyvasquez Aug 2005 A1
20050187617 Navia Aug 2005 A1
20050192606 Paul, Jr. et al. Sep 2005 A1
20050192665 Spenser et al. Sep 2005 A1
20050197692 Pai et al. Sep 2005 A1
20050197693 Pai et al. Sep 2005 A1
20050197694 Pai et al. Sep 2005 A1
20050203549 Realyvasquez Sep 2005 A1
20050203605 Dolan Sep 2005 A1
20050203614 Forster et al. Sep 2005 A1
20050203615 Forster et al. Sep 2005 A1
20050203616 Cribier Sep 2005 A1
20050203617 Forster et al. Sep 2005 A1
20050203618 Sharkawy et al. Sep 2005 A1
20050216039 Lederman Sep 2005 A1
20050216077 Mathis et al. Sep 2005 A1
20050216078 Starksen et al. Sep 2005 A1
20050222675 Sauter Oct 2005 A1
20050222678 Lashinski et al. Oct 2005 A1
20050228422 Machold et al. Oct 2005 A1
20050228479 Pavcnik et al. Oct 2005 A1
20050228486 Case et al. Oct 2005 A1
20050228494 Marquez Oct 2005 A1
20050228495 Macoviak Oct 2005 A1
20050228496 Mensah et al. Oct 2005 A1
20050234541 Hunt et al. Oct 2005 A1
20050234546 Nugent et al. Oct 2005 A1
20050240200 Bergheim Oct 2005 A1
20050240202 Shennib et al. Oct 2005 A1
20050240255 Schaeffer Oct 2005 A1
20050240259 Sisken et al. Oct 2005 A1
20050240262 White Oct 2005 A1
20050244460 Alferiev et al. Nov 2005 A1
20050246013 Gabbay Nov 2005 A1
20050251251 Cribier Nov 2005 A1
20050256566 Gabbay Nov 2005 A1
20050261704 Mathis Nov 2005 A1
20050261759 Lambrecht et al. Nov 2005 A1
20050267493 Schreck et al. Dec 2005 A1
20050267560 Bates Dec 2005 A1
20050267565 Dave et al. Dec 2005 A1
20050267571 Spence et al. Dec 2005 A1
20050267573 Macoviak et al. Dec 2005 A9
20050267574 Cohn et al. Dec 2005 A1
20050272969 Alferness et al. Dec 2005 A1
20050273160 Lashinski et al. Dec 2005 A1
20050278015 Dave et al. Dec 2005 A1
20050283178 Flagle et al. Dec 2005 A1
20050288779 Shaoulian et al. Dec 2005 A1
20060000715 Whitcher et al. Jan 2006 A1
20060004439 Spenser et al. Jan 2006 A1
20060004442 Spenser et al. Jan 2006 A1
20060009804 Pederson Jan 2006 A1
20060009841 McGuckin, Jr. et al. Jan 2006 A1
20060009842 Huynh et al. Jan 2006 A1
20060013805 Hebbel et al. Jan 2006 A1
20060013855 Carpenter et al. Jan 2006 A1
20060015136 Besselink Jan 2006 A1
20060015178 Moaddeb et al. Jan 2006 A1
20060015179 Bulman-Fleming et al. Jan 2006 A1
20060020275 Goldfarb et al. Jan 2006 A1
20060020327 Lashinski et al. Jan 2006 A1
20060020332 Lashinski et al. Jan 2006 A1
20060020334 Lashinski et al. Jan 2006 A1
20060020335 Kowalsky et al. Jan 2006 A1
20060020336 Liddicoat Jan 2006 A1
20060025750 Startksen et al. Feb 2006 A1
20060025784 Startksen et al. Feb 2006 A1
20060025787 Morales et al. Feb 2006 A1
20060025854 Lashinski et al. Feb 2006 A1
20060025855 Lashinski et al. Feb 2006 A1
20060025856 Ryan et al. Feb 2006 A1
20060025857 Bergheim et al. Feb 2006 A1
20060030747 Kantrowitz et al. Feb 2006 A1
20060030866 Schreck Feb 2006 A1
20060030882 Adams et al. Feb 2006 A1
20060030885 Hyde Feb 2006 A1
20060036317 Vidlund et al. Feb 2006 A1
20060041305 Lauterjung Feb 2006 A1
20060041306 Vidlund et al. Feb 2006 A1
20060047297 Case Mar 2006 A1
20060047338 Jenson Mar 2006 A1
20060047343 Oviatt et al. Mar 2006 A1
20060052804 Mialhe Mar 2006 A1
20060052867 Revuelta et al. Mar 2006 A1
20060058817 Starksen et al. Mar 2006 A1
20060058865 Case et al. Mar 2006 A1
20060058871 Zakay et al. Mar 2006 A1
20060058889 Case et al. Mar 2006 A1
20060064115 Allen et al. Mar 2006 A1
20060064116 Allen et al. Mar 2006 A1
20060064118 Kimblad Mar 2006 A1
20060064174 Zadno Mar 2006 A1
20060069400 Burnett et al. Mar 2006 A1
20060069429 Spence et al. Mar 2006 A1
20060069430 Rahdert et al. Mar 2006 A9
20060074483 Schrayer Apr 2006 A1
20060074484 Huber Apr 2006 A1
20060074485 Realyvasquez Apr 2006 A1
20060085060 Campbell Apr 2006 A1
20060089708 Osse et al. Apr 2006 A1
20060095115 Bladillah et al. May 2006 A1
20060095125 Chinn et al. May 2006 A1
20060099326 Keogh et al. May 2006 A1
20060100697 Casanova May 2006 A1
20060100699 Vidlund et al. May 2006 A1
20060106278 Machold et al. May 2006 A1
20060106279 Machold et al. May 2006 A1
20060106456 Machold et al. May 2006 A9
20060111660 Wolf et al. May 2006 A1
20060111773 Rittgers et al. May 2006 A1
20060111774 Samkov et al. May 2006 A1
20060116572 Case Jun 2006 A1
20060116756 Solem et al. Jun 2006 A1
20060122686 Gilad et al. Jun 2006 A1
20060122692 Gilad et al. Jun 2006 A1
20060122693 Biadillah et al. Jun 2006 A1
20060127443 Helmus Jun 2006 A1
20060129235 Seguin et al. Jun 2006 A1
20060129236 McCarthy Jun 2006 A1
20060135476 Kutryk et al. Jun 2006 A1
20060135964 Vesely Jun 2006 A1
20060135967 Realyvasquez Jun 2006 A1
20060136044 Osborne Jun 2006 A1
20060136045 Flagle et al. Jun 2006 A1
20060136052 Vesely Jun 2006 A1
20060136054 Berg et al. Jun 2006 A1
20060142846 Pavcnik et al. Jun 2006 A1
20060142847 Shaknovich Jun 2006 A1
20060142848 Gabbay Jun 2006 A1
20060142854 Alferness et al. Jun 2006 A1
20060149358 Zilla et al. Jul 2006 A1
20060149360 Schwammenthal et al. Jul 2006 A1
20060149367 Sieracki Jul 2006 A1
20060149368 Spence Jul 2006 A1
20060161133 Laird et al. Jul 2006 A1
20060161248 Case et al. Jul 2006 A1
20060161249 Realyvasquez et al. Jul 2006 A1
20060161250 Shaw Jul 2006 A1
20060167468 Gabbay Jul 2006 A1
20060167541 Lattouf Jul 2006 A1
20060167542 Quintessenza Jul 2006 A1
20060167543 Bailey et al. Jul 2006 A1
20070191928 Rolando et al. Aug 2007 A1
Foreign Referenced Citations (166)
Number Date Country
0 380 666 Aug 1990 EP
0 466 518 Jan 1992 EP
2 728 457 Jun 1996 FR
WO 8800459 Jan 1988 WO
WO 9015582 Dec 1990 WO
WO 9501669 Jan 1995 WO
WO 9619159 Jun 1996 WO
WO 9803656 Jan 1998 WO
WO 9846115 Oct 1998 WO
WO 9904724 Feb 1999 WO
WO 0067679 Nov 2000 WO
WO 0115650 Mar 2001 WO
WO 0117462 Mar 2001 WO
WO 03047468 Jun 2003 WO
WO 03084443 Oct 2003 WO
WO 2004019825 Mar 2004 WO
WO 2004021893 Mar 2004 WO
WO 2004023980 Mar 2004 WO
WO 2004030568 Apr 2004 WO
WO 2004030569 Apr 2004 WO
WO 2004030570 Apr 2004 WO
WO 2004032724 Apr 2004 WO
WO 2004032796 Apr 2004 WO
WO 2004037128 May 2004 WO
WO 2004037317 May 2004 WO
WO 2004039432 May 2004 WO
WO 2004043265 May 2004 WO
WO 2004043273 May 2004 WO
WO 2004043293 May 2004 WO
WO 2004045370 Jun 2004 WO
WO 2004045378 Jun 2004 WO
WO 2004045463 Jun 2004 WO
WO 2004047677 Jun 2004 WO
WO 2004060217 Jul 2004 WO
WO 2004060470 Jul 2004 WO
WO 2004062725 Jul 2004 WO
WO 2004066803 Aug 2004 WO
WO 2004066826 Aug 2004 WO
WO 2004069287 Aug 2004 WO
WO 2004075789 Sep 2004 WO
WO 2004080352 Sep 2004 WO
WO 2004082523 Sep 2004 WO
WO 2004082527 Sep 2004 WO
WO 2004082528 Sep 2004 WO
WO 2004082536 Sep 2004 WO
WO 2004082537 Sep 2004 WO
WO 2004082538 Sep 2004 WO
WO 2004082757 Sep 2004 WO
WO 2004084746 Oct 2004 WO
WO 2004084770 Oct 2004 WO
WO 2004089246 Oct 2004 WO
WO 2004089250 Oct 2004 WO
WO 2004089253 Oct 2004 WO
WO 2004091449 Oct 2004 WO
WO 2004091454 Oct 2004 WO
WO 2004093638 Nov 2004 WO
WO 2004093726 Nov 2004 WO
WO 2004093728 Nov 2004 WO
WO 2004093730 Nov 2004 WO
WO 2004093745 Nov 2004 WO
WO 2004093935 Nov 2004 WO
WO 2004096100 Nov 2004 WO
WO 2004103222 Dec 2004 WO
WO 2004103223 Dec 2004 WO
WO 2004105584 Dec 2004 WO
WO 2004105651 Dec 2004 WO
WO 2004112582 Dec 2004 WO
WO 2004112585 Dec 2004 WO
WO 2004112643 Dec 2004 WO
WO 2004112652 Dec 2004 WO
WO 2004112657 Dec 2004 WO
WO 2004112658 Dec 2004 WO
WO 2005000152 Jan 2005 WO
WO 2005002424 Jan 2005 WO
WO 2005002466 Jan 2005 WO
WO 2005004753 Jan 2005 WO
WO 2005007017 Jan 2005 WO
WO 2005007018 Jan 2005 WO
WO 2005007036 Jan 2005 WO
WO 2005007037 Jan 2005 WO
WO 2005009285 Feb 2005 WO
WO 2005009286 Feb 2005 WO
WO 2005009505 Feb 2005 WO
WO 2005009506 Feb 2005 WO
WO 2005011473 Feb 2005 WO
WO 2005011534 Feb 2005 WO
WO 2005011535 Feb 2005 WO
WO 2005013860 Feb 2005 WO
WO 2005018507 Mar 2005 WO
WO 2005021063 Mar 2005 WO
WO 2005023155 Mar 2005 WO
WO 2005025644 Mar 2005 WO
WO 2005027790 Mar 2005 WO
WO 2005027797 Mar 2005 WO
WO 2005034812 Apr 2005 WO
WO 2005039428 May 2005 WO
WO 2005039452 May 2005 WO
WO 2005046488 May 2005 WO
WO 2005046528 May 2005 WO
WO 2005046529 May 2005 WO
WO 2005046530 May 2005 WO
WO 2005046531 May 2005 WO
WO 2005048883 Jun 2005 WO
WO 2005049103 Jun 2005 WO
WO 2005051226 Jun 2005 WO
WO 2005055811 Jun 2005 WO
WO 2005055883 Jun 2005 WO
WO 2005058206 Jun 2005 WO
WO 2005065585 Jul 2005 WO
WO 2005065593 Jul 2005 WO
WO 2005065594 Jul 2005 WO
WO 2005070342 Aug 2005 WO
WO 2005070343 Aug 2005 WO
WO 2005072654 Aug 2005 WO
WO 2005072655 Aug 2005 WO
WO 2005079706 Sep 2005 WO
WO 2005082288 Sep 2005 WO
WO 2005082289 Sep 2005 WO
WO 2005084595 Sep 2005 WO
WO 2005087139 Sep 2005 WO
WO 2005087140 Sep 2005 WO
WO 2006000763 Jan 2006 WO
WO 2006000776 Jan 2006 WO
WO 2006002492 Jan 2006 WO
WO 2006004679 Jan 2006 WO
WO 2006005015 Jan 2006 WO
WO 2006009690 Jan 2006 WO
WO 2006011127 Feb 2006 WO
WO 2006012011 Feb 2006 WO
WO 2006012013 Feb 2006 WO
WO 2006012038 Feb 2006 WO
WO 2006012068 Feb 2006 WO
WO 2006012322 Feb 2006 WO
WO 2006019498 Feb 2006 WO
WO 2006026371 Mar 2006 WO
WO 2006026377 Mar 2006 WO
WO 2006026912 Mar 2006 WO
WO 2006027499 Mar 2006 WO
WO 2006028821 Mar 2006 WO
WO 2006029062 Mar 2006 WO
WO 2006031436 Mar 2006 WO
WO 2006031469 Mar 2006 WO
WO 2006032051 Mar 2006 WO
WO 2006034245 Mar 2006 WO
WO 2006035415 Apr 2006 WO
WO 2006041505 Apr 2006 WO
WO 2006044679 Apr 2006 WO
WO 2006048664 May 2006 WO
WO 2006050459 May 2006 WO
WO 2006050460 May 2006 WO
WO 2006054107 May 2006 WO
WO 2006054930 May 2006 WO
WO 2006055982 May 2006 WO
WO 2006060546 Jun 2006 WO
WO 2006063108 Jun 2006 WO
WO 2006063181 Jun 2006 WO
WO 2006063199 Jun 2006 WO
WO 2006064490 Jun 2006 WO
WO 2006065212 Jun 2006 WO
WO 2006065930 Jun 2006 WO
WO 2006066148 Jun 2006 WO
WO 2006066150 Jun 2006 WO
WO 2006069094 Jun 2006 WO
WO 2006070372 Jul 2006 WO
WO 2006073628 Jul 2006 WO
WO 2006076890 Jul 2006 WO
Related Publications (1)
Number Date Country
20060178730 A1 Aug 2006 US